What are the indications for FDG PET-CT (fluorodeoxyglucose positron emission tomography–computed tomography) in ovarian cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Indications for FDG PET-CT in Ovarian Cancer

FDG PET-CT is primarily indicated for detecting recurrent ovarian cancer, particularly when there is high clinical suspicion (rising CA-125 or symptoms) but indeterminate CT findings, and for post-treatment response assessment. 1

Primary Clinical Indications

1. Recurrence Detection (Strongest Indication)

  • Use when CT is indeterminate despite high clinical suspicion based on:

    • Rising CA-125 levels
    • Worsening clinical symptoms
    • Abnormal physical examination findings 1

  • Performance characteristics: FDG PET-CT demonstrates 88% sensitivity and 89% specificity for diagnosing recurrent epithelial ovarian cancer 1

  • Clinical advantage: Can detect recurrence even when CA-125 is normal or when contrast-enhanced CT is negative 2

2. Post-Treatment Response Assessment

FDG PET-CT is a recommended complementary study (alongside CT abdomen/pelvis and CT chest with IV contrast) for evaluating post-treatment response 1

3. Initial Staging (Limited Role)

  • May be appropriate for preoperative staging, though not first-line 1
  • Shows improved specificity over CT alone for detecting stage III disease, though sensitivity is comparable 1
  • Most useful for identifying distant metastatic disease (peritoneal and lymph node metastases) when lesion characterization may alter clinical management 1

Important Limitations to Recognize

Technical Limitations

  • Poor detection of subcentimeter metastases due to suboptimal spatial resolution 1
  • High FDG concentration near bladder obscures pelvic lesions 1
  • Metabolic activity in/between bowel loops difficult to assess, especially post-surgery when adhesions or inflammation present 1

False Results

  • False positives: Inflammatory processes, fungal infections, post-surgical adhesions 3
  • False negatives: Certain histologic subtypes (mucinous and clear cell carcinomas may show low FDG uptake) 4

Clinical Decision Algorithm

For suspected recurrence:

  1. Start with contrast-enhanced CT abdomen/pelvis and chest
  2. If CT is indeterminate AND clinical suspicion remains high (rising CA-125, symptoms) → proceed to FDG PET-CT 1
  3. If CT is clearly positive or clearly negative → FDG PET-CT generally not needed

For post-treatment assessment:

  • FDG PET-CT serves as a complementary study to CT imaging for response evaluation 1

For initial staging:

  • CT with IV contrast remains the primary modality
  • Consider FDG PET-CT only when lesion characterization might alter management decisions 1

Key Caveats

  • Never use PET-CT alone to make surgical decisions; positive findings require histologic confirmation 3
  • Negative PET-CT does not exclude cancer; further workup remains indicated if clinical suspicion persists 3
  • In asymptomatic patients in clinical remission, the role of routine surveillance PET-CT is unclear and not recommended 1

The 2025 ACR Appropriateness Criteria 1 represent the most current and authoritative guidance, establishing FDG PET-CT's primary value as a problem-solving tool for recurrence detection rather than routine screening or initial staging.

References

1
Guideline

acr appropriateness criteria® staging and follow-up of ovarian cancer: 2025 update.

Journal of the American College of Radiology, 2025

Related Questions

Should a whole-body 18F‑FDG PET/CT be performed for staging in a reproductive‑age female with a suspected ovarian dysgerminoma?
What is the role of sildenafil in a patient with pulmonary hypertension secondary to atrial fibrillation?
In a patient with hypertension taking losartan 100 mg daily, spironolactone 25 mg daily, metoprolol tartrate 100 mg twice daily, and furosemide (Lasix) 20 mg daily, should the loop diuretic be continued for volume control or switched to a thiazide‑like diuretic?
When is ursodeoxycholic acid (UDCA) indicated in pregnancy, and what is the recommended dosage and safety profile?
What is the role of N‑acetylcysteine in an adult patient with hypertension‑induced chronic kidney disease who is on maintenance hemodialysis?
A patient received adenosine 49 mg at 1600 h today; can apixaban be started today or should it be delayed until tomorrow?
In ovarian cancer, when should FAPI PET‑CT be used instead of FDG PET‑CT, and how do they compare for detecting recurrence and assessing treatment response?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.